MedTrace Logo

Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis

NCT05151848 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-07-24

No results posted yet for this study

Summary

This is a prospective,open-labelled,multi-center,randomized clinical trial.It compares the clinical efficacy and safety of there 2 drugs in the treatment of relapse active Takayasu's arteritis patients.

Conditions

  • Takayasu Arteritis

Interventions

DRUG

Adalimumab Injection

Adalimumab Injection injected subcutaneously every other week for 78 weeks

DRUG

Tofacitinib 5 MG

Tofacitinib 5 MG BID taken orally for 78 weeks

Sponsors & Collaborators

  • Chinese SLE Treatment And Research Group

    lead OTHER

Principal Investigators

  • Xiaofeng Zeng, MD · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-05
Primary Completion
2026-01-15
Completion
2026-01-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05151848 on ClinicalTrials.gov